<h1>India Grants Compulsory License for Anti-Cancer Drug Sorafenib Tosylate u/s 84; Dasatinib Still Under Review.</h1> The Controller General of Patents in India has granted one compulsory license for the anti-cancer drug Sorafenib Tosylate, used for kidney and liver cancer, to a manufacturing company. This license, under Section 84 of the Patent Act, was originally held by a U.S. corporation. The Ministry of Health and Family Welfare recommended compulsory licensing for three other drugs, but only Dasatinib remains under consideration. Herceptin's patent was not renewed, and Ixabepilone was deemed unsafe. The information was disclosed by the Minister of State in the Ministry of Commerce and Industry in a written reply to the Lok Sabha.